Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
| 5.37 | |
| 5.26 | |
| - | |
| 5.42 | |
| 5.23 | |
| 3.86-9.12 | |
| 660 M | |
| 126 M | |
| 19 608 K | |
| -0.21 | |
| 0.844 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Whether investors refer to them as undervalued or hidden gems, underappreciated stocks are always worth considering. Investors have made fortunes, large and small, by identifying underappreciated sha...
It’s no secret that artificial intelligence (AI) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stoc...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
